Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma

Blood (2025) 146 (Supplement 1): 2214.

https://doi.org/10.1182/blood-2025-2214

Published: 2025

Journal Articles

Nfkb signaling in idecabtagene vicleucel infusion product drives response in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 504.

https://doi.org/10.1182/blood-2025-504

Published: 2025

Journal Articles

Oral Care™ kit as a prophylaxis for talquetamab-associated toxicities in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 7574.

https://doi.org/10.1182/blood-2025-7574

Published: 2025

Journal Articles

ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.

Blood (2025) 146 (Supplement 1): 5846.

https://doi.org/10.1182/blood-2025-5846

Published: 2025

Journal Articles

Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis

Blood (2025) 146 (Supplement 1): 5833.

https://doi.org/10.1182/blood-2025-5833

Published: 2025

Journal Articles

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Surbhi Sidana, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Alexis Castaneda Puglianini, Gabriel De Avila, Christian Gordillo, Eli Zolotov, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen

Blood (2025) 146 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2025-1034

Published: 2025

Journal Articles

Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.

Blood (2025) 146 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2025-4066

Published: 2025

Journal Articles

Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4051.

https://doi.org/10.1182/blood-2025-4051

Published: 2025

Journal Articles

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Ran Reshef, Alexandria Jensen, Christian Gordillo, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Puglianini, Gabriel De Avila, Eli Zolotov, Evguenia Bhurtel, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen, Surbhi Sidana

Blood (2025) 146 (Supplement 1): 134.

https://doi.org/10.1182/blood-2025-134

Published: 2025

Journal Articles

Real-time multimodal AI outperforms conventional scores for early risk prediction in BCMA CAR-T–Treated myeloma

Blood (2025) 146 (Supplement 1): 6140.

https://doi.org/10.1182/blood-2025-6140

Published: 2025

Journal Articles

Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes

Blood (2025) 145 (15): 1645–1657.

https://doi.org/10.1182/blood.2024024965

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Blood (2025) 145 (1): 85–97.

https://doi.org/10.1182/blood.2024025945

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience

Blood (2024) 144 (Supplement 1): 7832.

https://doi.org/10.1182/blood-2024-204276

Published: 2024

Journal Articles

Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity

Blood (2024) 144 (Supplement 1): 5165.

https://doi.org/10.1182/blood-2024-208529

Published: 2024

Journal Articles

Single-Cell Analysis of CAR-T Cell Products Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Reveals Factors That Influence Clinical Outcomes

Jerald Noble, Xiaofei Song, Meghan Menges, Julieta Abraham-Miranda, Salvatore Corallo, Gabriel De Avila, Omar Puglianini, Hien Liu, Melissa Alsina, Taiga Nishihori, Kenneth H. Shain, Rachid Baz, Brandon Blue, Ariel Grajales-Cruz, Doris K. Hansen, Reginald Atkins, Frederick L. Locke, Ciara Louise Freeman

Blood (2024) 144 (Supplement 1): 7173.

https://doi.org/10.1182/blood-2024-208709

Published: 2024

Journal Articles

The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma

Praneeth Reddy Sudalagunta, David R. Noyes, Gabriel De Avila, Alexandra Achille, Rafael Renatino-Canevarolo, Xiaohong Zhao, Maria Silva, Angel Perez, Mark B. Meads, Lauren C. Peres, Doris K. Hansen, Kenneth H. Shain, Ariosto Siqueira Silva

Blood (2024) 144 (Supplement 1): 4645.

https://doi.org/10.1182/blood-2024-205631

Published: 2024

Journal Articles

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 897.

https://doi.org/10.1182/blood-2024-203409

Published: 2024

Journal Articles

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 896.

https://doi.org/10.1182/blood-2024-197929

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Trajectories of Patient-Reported Outcomes after Idecabtagene Vicleucel Vs. Ciltacabtagene Autoleucel CAR T-Cell Therapy Among Patients with Relapsed/Refractory Multiple Myeloma in Standard of Care

Blood (2024) 144 (Supplement 1): 7842.

https://doi.org/10.1182/blood-2024-208668

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma

Nfkb signaling in idecabtagene vicleucel infusion product drives response in relapsed/refractory multiple myeloma

Oral Care™ kit as a prophylaxis for talquetamab-associated toxicities in patients with Relapsed/Refractory multiple myeloma

ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.

Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.

Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Real-time multimodal AI outperforms conventional scores for early risk prediction in BCMA CAR-T–Treated myeloma

Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience

Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity

Single-Cell Analysis of CAR-T Cell Products Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Reveals Factors That Influence Clinical Outcomes

The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Trajectories of Patient-Reported Outcomes after Idecabtagene Vicleucel Vs. Ciltacabtagene Autoleucel CAR T-Cell Therapy Among Patients with Relapsed/Refractory Multiple Myeloma in Standard of Care

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only